This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term care facilities, and medical equipment and supplies. Companies in this sector include Astra Zeneca, Pfizer and Roche Holding.
In QuotedData’s morning briefing 8 March 2023: Syncona’s (SYNC’s) portfolio company Autolus Therapeutics has announced its operational and financial results for the full year ended December 31, 2022. Key highlights included: The FELIX study of obe-cel in relapsed/refractory (r/r) adult acute lymphoblastic leukemia (ALL) met its primary endpoint; remains on track for a next data […]
RTW Venture Fund has drawn investors’ attention to positive data updates on two clinical trials of Prometheus Biosciences, Inc. (NASDAQ: RXDX), its third largest holding, representing about 7.5% of NAV. Prometheus is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for […]
In QuotedData’s Morning briefing 9 December 2022: Syncona’s (SYNC’s) portfolio company Autolus Therapeutics Plc has announced the pricing of its underwritten public offering, in the US, of 75m American Depositary Shares (ADSs). These represent 75m ordinary shares and were issued at a price of US$2.00 per ADS, for total gross proceeds of approximately US$150m (£122.5m). […]
RTW was a co-lead in a $149m Series B financing round for Apogee Therapeutics, LLC, a biotechnology company focused on immunological and inflammatory disorders. RTW Venture participated in the fundraise but we have not been not told what its contribution was. Proceeds from the financing will be used to support Apogee’s plans to advance its […]
In QuotedData’s morning briefing 23 November 2022: Worldwide Healthcare (WWH) has announced its interim results for the six months ended 30 September 2022. During the period, WWH provided an NAV total return of 3.1%, modestly outperforming its benchmark, the MSCI World Healthcare Index, which returned 2.1% during the period. In absolute terms, net asset value […]
BioPharma Credit (BPCR) has announced that, together with BioPharma Credit Investments V, it has entered into a senior secured loan agreement with Immunocore Limited. BPCR will invest up to US$50m and BioPharma-V will also invest up to an additional US$50m. Based in the UK, Immunocore is a publicly traded biopharmaceutical company with a current market […]
A new Guernsey domiciled investment company, Conviction Life Sciences (CLSC), published a prospectus on 16 November 2022 for its initial public offering (IPO). The prospectus is availale here. The IPO is targeting gross proceeds of £100m and CLSC plans to list on the main market of the London Stock Exchange. It is expected that CLSC’s […]
Biotechnology is an exciting and potentially rewarding sector for investment but for the private investor it is also risky and probably best addressed through collective investment vehicles. After all, development of new drugs is hugely expensive (and thus funding-dependent), scientifically uncertain and fraught with operational challenges and pitfalls. And adding to this is the fact […]
BB Biotech saw an almost 3% rise in its NAV yesterday to CHF51/share, helped by a 36% jump in the share price in one of its holdings – Myovant – triggered by a cash buy-out offer. BB Biotech’s share price, however, was largely unchanged at CHF52.8, which has had the effect of reducing the investment […]
Switzerland’s BB Biotech has opened a new investment position in Rivus Pharmaceuticals, a privately held US biotech developing a mitochondrial-based approach to obesity and cardio-metabolic disease. This was made as part of a $132m Series B financing that is notable for its size and the top-tier syndicate of healthcare specialist investors who have participated. The […]
In QuotedData’s morning briefing 16 September 2022: RTW Venture’s (RTW’s) portfolio company, Third Harmonic Bio Inc., has completed its initial public offering (IPO) and has listed on Nasdaq (ticker: THRD). The upsized issue raised US$185.3m by offering around 10.7m shares at US$17.00 per share. Third Harmonic Bio is a clinical-stage biotechnology company developing a first-in-class, […]
In early 2021, it looked like the pandemic had been a breakthrough moment for the biotechnology sector. The sector had been critical in the development of Covid-19 vaccines, using new and innovation gene sequencing, while developments in oncology promised a treatment revolution. Share prices were riding high and specialist investment trusts had enjoyed two years […]
BB Biotech shares closed yesterday at CHF 57 per share, down 26.5% in the year-to-date period, but crucially up by 12% since mid-June when the shares hit a recent nadir of CHF51 per share. NAV, at CHF49.95 per share, is down by 9.95% year-to-date (YTD), but has gained 22% from its recent nadir of CHF40.9 […]
Syncona’s results for the financial year ended 31 March 2022 show an NAV total return of just 0.3%. However, this was a long way ahead of the -12% return on the NASDAQ Biotechnology Index. A significant NAV uplift achieved through the sale of Gyroscope to Novartis and multiple successful private financings offset the decline in […]
Following the announcement earlier today that it has terminated its placing programme (click here to read more), Worldwide Healthcare (WWH) has now announced its annual results for the year ended 31 March 2022. These show that, following the previous year’s strong returns, both on an absolute and on a relative basis, the year under review […]
In QuotedData’s morning briefing 27 May 2022: Worldwide Healthcare (WWH) has announced that it is terminating its placing programme, which was established on 13 July 2021, with immediate effect. WWH expects to publish its annual results later today and, if the placing programme was still in effect, this would have required WWH to publish a […]
In QuotedData’s morning briefing 13 May 2021: Barings Emerging EMEA Opportunities (BEMO) has announced that Maria Szczesna, one of its investment managers, and a member of the Barings EMEA Team, has decided to step down from her portfolio management responsibilities to return to her home country for family reasons. Maria will remain with BEMO until […]
BB Biotech (SWX:BION) has continued to show a resilient performance this year, a period that has proved to be extremely challenging for biotech investing – indeed the sector is now considered to be experiencing its most severe bear market for more than two decades. BB Biotech’s shares closed on Friday at CHF 56.00, down 23% […]
BB Biotech (SWX:BION) showed a resilient investment performance in an extremely difficult period for biotech in the first quarter this year, although its NAV, share price and long standing premium have all clearly come under pressure. The Swiss investment company closed the first quarter of 2022 with its shares trading at CHF65.4, down by 10.3%, […]
In QuotedData’s morning briefing 11 March 2022: CQS Natural Resources Growth and Income (CYN) has announced its interim results for the six months ended 31 December 2021. CYN’s chairman, Richard Prickett says that, during the period, commodity markets were strong and interestingly for the sector higher interest rate expectations are supporting a broad market rotation […]
RTW makes two investments: Magnolia Medical Technologies RTW says that Magnolia Medical Technologies has completed a $46m growth equity financing round. The company, alongside other investment vehicles of RTW Investments, LP, participated in the financing round together with other investors. Magnolia Medical is a privately held medical technology company that develops, manufactures, and markets innovative […]
With valuations in biotech having fallen substantially in the last year, BB Biotech (SWX: BION) sees compelling opportunities in the small-to-mid cap space this year and believes some of its core portfolio companies, such as Neurocrine, Incyte and Ionis Pharmaceuticals, could see interest from strategic investors, including as M&A targets. The comments come in the […]
BB Biotech (SWX: BION) seems to be resilient in the current challenging period for biotech investing and most especially in the last week, which ranks as one of the most important trading periods in the biotech calendar. The Swiss investment company saw a 0.8% fall in its NAV in the five days from January 10-14th […]
Swiss investment company BB Biotech (SWX:BION) closed 2021 with its shares trading at CHF77.15, a rise by 8.3% over the year. However, the positive stock performance contrasts with an 11.4% fall in its NAV to CHF59.4/share in 2021, which was adversely affected by the severe bear market for biotech – and particularly its small to […]
Polar Capital Global Healthcare (PCGH) has released its annual results for the year ended 30 September 2021, during which it has provided NAV and share price total returns of 19.46% and 24.55%, strongly outperforming its benchmark, the MSCI ACWI Health Care Index, which returned 13.40%. Since its restructuring to 30 September 2021, PCGH has provided […]
Syncona’s Anaveon secures Series B financing – Syncona has committed CHF35m (£29m) to Anaveon AG as part of a CHF110m (£90m) Series B financing round. Syncona was a cornerstone investor. The financing round was led by Forbion and supported by a leading international syndicate of specialist investors, including existing investor Novartis Venture Fund and new investors […]
Syncona backs launch of Clade Therapeutics – Syncona was the lead investor in the $87m Series A financing of Clade Therapeutics, a new cell therapy company. Syncona’s commitment was $30m and the first tranche of that – $15.0m – has been invested already. Syncona’s stake in the company is 22.6% (assuming all commitments are invested). […]
BB Biotech has disclosed an increase in its holding in Mersana Therapeutics (Nasdaq:NRSN), the timing of which suggests it again aims to capitalise on a 40% fall in an investee company’s share price that occurred after a clinical trial update earlier in the month. The Swiss investment company disclosed the increased holding in a SEC […]
In QuotedData’s morning briefing 10 September 2021: RTW Venture (RTW) has announced a new portfolio investment in Lycia Therapeutics, following its participation in the company’s US$70m series B financing round, the proceeds of which are intended to advance Lycia’s discovery pipeline of LYTAC degraders. Lycia is a privately held biotechnology company developing extracellular protein degradation […]
Swiss investor BB Biotech’s (SWX:BION) large position in US covid vaccine producer Moderna continues to drive a remarkable performance in a volatile US biotech market. Yesterday, Moderna (Nasdaq: MRNA) surged 17% to a new all-time high of $484.5/share, giving it a market capitalisation of $167bn. Moderna is the largest of BB Biotech’s holdings accounting for […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated